Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. It offers Midazolam for epileptic seizure; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In addition, the company is developing ZEPIZURE, an emergency treatment for managing epileptic seizures. The company was incorporated in 2001 and is based in Dijon, France.
Name | Title | Since | Age |
|---|---|---|---|
| Philippe Monnot | Chairman of Supervisory Board | - | - |
| Eric Nemeth | Independent Vice Chairman of the Supervisory Board | 2012 | - |
| Jean-Francois Loumeau | Member of Supervisory Board | 2018 | - |
| Yannick Pletan | Member of Supervisory Board | 2019 | 73 |
| Daniel Gedeon Teper | Member of Supervisory Board | 2023 | 67 |